Observational Study to Estimate the Proportion of Post-operative Infection Following Excision of Ulcerated Skin Tumours
Conditions: Skin Cancer
Sponsor: Cardiff and Vale University Health Board

 
 
 
 
 
 
 
Page 0 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
0 
ObservAtional study to investigate 
Surgical site Infection in ulcerated Skin 
cancers (OASIS): 
 
Observational study to estimate the proportion of post-operative infection following excision 
of ulcerated skin tumours. 
PROTOCOL VERSION NUMBER 1.3 
 
10/12/19 
Sponsor:  
 
Cardiff and Vale University Health Board (CAVUHB) 
Sponsor ref: 
RD 17/DEC/7165 
Funders: 
UK Dermatology Clinical Trials Network (UK DCTN)  
Dermatology Forum for Wales 
CAVUHB Dermatology Department Research Funds  
Funder ref: 
UK DCTN Pump Priming Award 2017 
REC ref: 
19/SC/0047 
IRAS number: 
243011 
NCT number: 
NCT03782727 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
Page 1 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
1 
 
 
SIGNATURE PAGE 
The undersigned confirm that the following protocol has been agreed and accepted and that 
the Chief Investigator agrees to conduct the study in compliance with the approved protocol 
and will adhere to the principles outlined in the relevant study regulations and GCP guidelines. 
I agree to ensure that the confidential information contained in this document will not be used 
for any other purpose other than the evaluation or conduct of the clinical investigation without 
the prior written consent of the Sponsor. 
I also confirm that I will make the findings of the study publically available through publication 
or other dissemination tools without any unnecessary delay and that an honest accurate and 
transparent account of the study will be given; and that any discrepancies from the study as 
planned in this protocol will be explained. 
 
Chief Investigator: 
 
 
 
 
 
 
 
Name 
Signature 
Date 
 
General Information This protocol describes the OASIS clinical study, and provides 
information about the procedures for entering participants into the study. The protocol should 
not be used as a guide, or as an aide-memoire for the treatment of other participants. Every 
care has been taken in drafting this protocol; however, corrections or amendments may be 
necessary. These will be circulated to the known Investigators in the study.  
 
 
 

 
 
 
 
 
 
 
Page 2 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
2 
Contact details – Chief Investigator & Co-Investigators 
CHIEF INVESTIGATOR 
CO-INVESTIGATORS 
Dr Rachel Abbott 
Dr Rubeta Matin 
Consultant Dermatologist 
Consultant Dermatologist 
The Welsh Institute of Dermatology 
Oxford University Hospitals NHS Foundation 
Trust 
University Hospital of Wales 
rnhmatin@doctors.org.uk 
CF14 4XW 
 
Tel : 02920 743181 
 
E-mail : rachel.abbott@wales.nhs.uk 
 
 
 
Dr Agustin Martin-Clavijo 
Dr Aaron Wernham 
Consultant Dermatologist,                                 
University Hospitals Birmingham NHS 
Foundation Trust  
Dermatology Registrar, University Hospitals 
Birmingham NHS Foundation Trust  
E-mail: agustin.martin-clavijo@uhb.nhs.uk 
E-mail : aaron.wernham@nhs.net 
 
Dr Stela Ziaj  
Dr Robin Howe 
Dermatology Registrar, Cardiff and Vale 
University Health Board 
Consultant Microbiologist, Cardiff and Vale 
University Health Board 
Email: stela.ziaj@wales.nhs.uk 
 
Dr Emma Thomas-Jones 
E-mail : robin.howe@wales.nhs.uk 
 
Tim Pickles 
Research Fellow/ Senior Trial Manager 
Research Associate in Statistics 
Cardiff University 
Cardiff University 
E-mail: Thomas-JonesE@cardiff.ac.uk 
E-mail: PicklesTE@cardiff.ac.uk 

 
 
 
 
 
 
 
Page 3 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
3 
 
 
 
 
SPONSOR contact details:  
Cardiff and Vale University Health Board 
University Hospital of Wales 
Heath Park 
Cardiff CF14 4XW 
 
 
 
 
 
 
 
 
 
 
Study Co-ordination: 
The OASIS study is being coordinated by Dr Emma Thomas-Jones,  
 
 
Research Fellow/ Senior Trial Manager 
Centre for Trials Research 
College of Biomedical & Life Sciences 
Cardiff University 
7th Floor, Neuadd Meirionnydd 
Heath Park 
Cardiff CF14 4YS 
E-mail: Thomas-JonesE@cardiff.ac.uk 
Tel: +44(0)29 20687520 
 
 

 
 
 
 
 
 
 
Page 4 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
4 
Table of Contents 
1 Amendment History .............................................................................................. 7 
2 Synopsis ........................................................................................................... 9 
3 Study summary & schema .................................................................................... 11 
3.1 
Participant flow diagram ............................................................................ 11 
3.2 
Study lay summary .................................................................................. 11 
4 Background ...................................................................................................... 12 
5 Study objectives/endpoints and outcome measures ...................................................... 13 
5.1 
Primary objectives ................................................................................... 13 
5.2 
Secondary objectives ............................................................................... 13 
5.3 
Primary outcomes measure ....................................................................... 13 
5.4 
Secondary outcomes measure(s) ................................................................ 14 
6 Study design and setting ...................................................................................... 14 
6.1  
Risk assessment .................................................................................... 15 
7 Site and Investigator selection................................................................................ 16 
8 Participant selection ............................................................................................ 16 
8.1 
Inclusion criteria ..................................................................................... 16 
8.2 
Exclusion criteria .................................................................................... 16 
9 Recruitment, Screening and registration .................................................................... 16 
9.1 
Participant identification ............................................................................ 16 
9.2 
Screening logs ....................................................................................... 16 
9.3 
Recruitment rates ................................................................................... 16 
9.4 
Informed consent .................................................................................... 17 
9.5 
Registration .......................................................................................... 18 
9.5.1 
Registration ....................................................................................... 18 
10 Withdrawal & lost to follow-up ................................................................................ 18 
10.1 
Withdrawal............................................................................................ 18 
10.2 
Lost to follow up ..................................................................................... 18 
11 Study procedures ............................................................................................... 18 
11.1 
Assessments ......................................................................................... 19 
11.2 
Follow-up ............................................................................................. 20 
11.3 Skin swabs (UHW participants only) ................................................................... 20 
12 Statistical considerations ...................................................................................... 21 
12.1 Sample size ................................................................................................ 21 
12.2 Missing, unused & spurious data ....................................................................... 21 
12.3 Procedures for reporting deviation(s) from the original protocol ................................... 21 
12.4 Inclusion in analysis ...................................................................................... 22 
13 Analysis .......................................................................................................... 22 
13.1 Main analysis .............................................................................................. 22 
14 Data Management .............................................................................................. 22 
14.1 Access to Data ............................................................................................ 22 
14.2 Data Recording and Record Keeping .................................................................. 22 
14.3 Participant Confidentiality and Data Protection ...................................................... 24 
14.4 Record Storage and Retention ......................................................................... 24 
15 Protocol/GCP non-compliance ............................................................................... 25 
16 End of Study definition ......................................................................................... 25 
17 Regulatory Considerations .................................................................................... 26 
17.1 Ethical and governance approval ....................................................................... 26 
17.2 Data Protection ............................................................................................ 26 
17.3 Indemnity ................................................................................................... 26 

 
 
 
 
 
 
 
Page 5 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
5 
17.4 Study sponsorship ........................................................................................ 26 
17.5 Funding ..................................................................................................... 27 
18 Quality Control and Assurance ............................................................................... 27 
18.1 
Monitoring ............................................................................................ 27 
19 Publication policy ............................................................................................... 27 
20 References ...................................................................................................... 28 
21 Appendices ...................................................................................................... 30 
  

 
 
 
 
 
 
 
Page 6 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
6 
Glossary of abbreviations 
 
 
CAVUHB 
CI 
Cardiff and Vale University Health Board 
Chief Investigator 
CRF 
Case Report Form 
CTR 
Centre for Trials Research 
GCP 
Good Clinical Practice 
GP 
General Practitioner 
HB 
HCRW 
HRA 
OASIS 
Health Board 
Health and Care Research Wales 
Health Research Authority 
Observational study to investigate surgical site infection in ulcerated skin 
cancers 
PI 
Principal Investigator 
R&D 
Research and Development 
REC 
SSI 
UK DCTN 
Research Ethics Committee 
Surgical site infection 
UK Dermatology Clinical Trials Network 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
Page 7 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
7 
1 
Amendment History 
The following amendments and/or administrative changes have been made to this protocol 
since the implementation of the first approved version. 
Amendment 
No. 
(specify 
substantial/non-
substantial) 
Protocol 
version 
no. 
Date 
issued 
Summary of changes made since 
previous version 
Non-substantial 
1.2 
19/03/19 
p.18: ‘type of procedure’ added to 
paragraph 3 ie. data recorded after skin 
surgery 
p.22: ‘type of procedure’ added to list of 
data recorded on Case Report Form. 
Non-substantial 
1.3 
04/12/19 
p.19: 
• ‘Whether the participant has been 
recruited to the study previously 
•  Number of skin lesions being excised 
• Number of skin lesions being excised 
that are ulcerated  (if more than one 
ulcerated lesion, then the patient and 
researcher should agree on an index 
lesion for the OASIS study)’ 
 
Above text added to paragraph 1 ie. data 
recorded before surgery with additional 
changes highlighted in red below: 
• Suspected type of index skin cancer 
(clinical diagnosis) – to be confirmed on 
histology 

 
 
 
 
 
 
 
Page 8 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
8 
• Site of procedure(s) 
• Size of index skin cancer (mm) 
• Size of index tumoral ulceration 
p.22-3: 
• ‘Whether the participant has been 
recruited to the study previously 
•  Number of skin lesions being excised 
• Number of skin lesions being excised 
that are ulcerated  (if more than one 
ulcerated lesion, then the patient and 
researcher should agree on an index 
lesion for the OASIS study)’  
 
Above text added to list of data recorded 
on Case Report Form with additional 
changes highlighted in red below: 
• Suspected type of index skin cancer 
(clinical diagnosis) – to be confirmed on 
histology 
• Site of procedure(s) 
• Size of index skin cancer (mm) 
• Size of index tumoral ulceration (mm) 
 
List summary of protocol amendments here whenever a new version of the protocol is 
produced. Ensure details are also updated in a full protocol change log. 

 
 
 
 
 
 
 
Page 9 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
9 
2 
Synopsis 
Short title 
ObservAtional study to investigate Surgical site Infection in ulcerated 
Skin cancers 
Acronym 
OASIS 
Internal ref. no. 
 
Clinical phase  
N/A 
Funder and ref. 
UK Dermatology Clinical Trials Network (UK DCTN)  
Dermatology Forum for Wales 
CAVUHB Dermatology Department Research Funds 
Study design 
Observational prospective study 
Study participants 
People undergoing surgical excision of ulcerated skin cancer of any 
type at any body site in the dermatology departments at the University 
Hospital of Wales Cardiff; Churchill Hospital, Oxford and Queen 
Elizabeth Hospital, Birmingham. 
Planned sample size 
311 
Inclusion criteria 
> 18 years old 
 
Exclusion criteria 
1) Evidence of wound infection at the time of the procedure 
2) Skin tumour removal undertaken curettage or Mohs micrographic 
surgery  
3) People without the capacity to consent for the study  
4) People who are on systemic immunosuppressive treatment  
5) People who are already taking oral antibiotics 
 
Treatment duration 
N/A 

 
 
 
 
 
 
 
Page 10 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
10 
Follow-up duration 
4 weeks 
Planned study 
period 
8 months (recruitment phase) + 1 month (follow-up phase) + 5 months 
(analysis and write up phase) 
Primary objective 
To ascertain the proportion of surgical site infections following excision 
of ulcerated skin tumours in Dermatology Departments. 
Secondary 
objectives 
Feasibility work to inform the design of a future randomised controlled 
trial to investigate whether the use of peri-operative antibiotics in 
ulcerated skin tumours reduces the proportion of patients with surgical 
site infection. 
Primary outcomes 
Proportion of participants with surgical site infection (SSI) identified by 
postal questionnaire four weeks after surgery. 
Secondary 
outcomes 
a) The proportion of participants, over eight months from screened, 
eligible and willing to be randomised in a future trial to: 
a. no treatment 
b. topical treatment 
c. a few days of oral antibiotics 
d. a week of oral antibiotics  
b) The proportion of participants recruited over eight months from 
eligible. 
c) The proportion of participants completing the study (responding to the 
postal questionnaire) over eight months from eligible. 
d) Assess feasibility of ‘wound selfies’ or wound photographs taken in 
the department as an objective outcome measure. 
e) The proportion of participants with SSI who were prescribed oral 
antibiotics at the time of surgery. 
f) Ulcerated tumour swab analysis results. 
Intervention 
N/A 
 

 
 
 
 
 
 
 
Page 11 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
11 
3 
Study summary & schema 
3.1 
Participant flow diagram 
 
3.2 
Study lay summary 
Study title: ObservAtional study to investigate Surgical site Infection in ulcerated Skin cancers 
(OASIS) 
We aim to recruit 311 participants to this study from three UK Dermatology departments. We 
will invite people with suspected skin cancers whose lesions have a broken surface (also 
known as ulcerated) who will undergo surgery.  
This study is being carried out because it is possible that patients with skin cancers with 
ulceration might be at greater risk of developing a wound infection after surgery. The aim of 
this study is to determine how many people with ulcerated skin cancers develop an infection 
of the wound after it has been surgically removed.  
People with ulcerated skin cancers who will have surgery will be invited to participate in the 
study. If they agree, a member of the research team will explain the study and consent them 
to participate in the study. At the time of surgery, information will be collected about the 
participant, skin tumour and procedure. The participant will be given standardised advice 
Enrollment
Observation at time of 
procedure (+ skin swab 
for CAVUHB participants)
Questionnaire four 
weeks after procedure
Analysis

 
 
 
 
 
 
 
Page 12 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
12 
regarding wound care and further care will be as per each centre’s ‘normal clinical care’. If 
participants are diagnosed with a wound infection then they will asked to take a ‘wound selfie’ 
and share the photo with the research team. The research team will contact the participant via 
questionnaire which will be sent four weeks by post or e-mail after the procedure to determine 
whether they had any concerns about post-operative infection and whether any action was 
taken. 
Additionally, all participants at the University Hospital of Wales will have a surface swab taken 
from their ulcerated skin cancer and these will be analysed in the Public Health Wales 
laboratory at the University Hospital of Wales, Cardiff. The aim of this aspect of the study is to 
identify the most common bacteria in ulcerated tumours. 
4 
Background 
Non-melanoma skin cancer is the most common cancer in the UK with a rising worldwide 
incidence.1 For the majority of patients, surgical excision remains the gold standard 
treatment, however the role of peri-operative antibiotics in preventing post-operative infection 
remains controversial. Ulcerated tumours occur commonly in dermatological surgical lists 
ranging from 19-33%.2-4 In a prospective evaluation of excised skin cancers by our group, 
including patients undergoing excision at the University Hospital of Wales, Cardiff and the 
Queen Elizabeth Hospital, Birmingham, one third of skin cancers were clinically ulcerated.  
The true proportion of patients developing post-operative infection following surgery in 
ulcerated skin cancers is needed to determine the sample size for a randomised controlled 
trial to evaluate the potential benefit of peri-operative antibiotics. Few studies have assessed 
this accurately although rates of infection have been reported to be as high as 33% in a 
small single-centre cohort study.2 A recently published randomised controlled trial reported 
SSI in 30% of participants with ulcerated tumours undergoing excision who were not 
randomised to receive perioperative intravenous cefazolin.5 This is significantly higher than 
quoted figures for all skin cancer excisions (2-8%).6-8 A larger Australian study reported a 
three-fold increase in the risk of post-operative infection for excision of ulcerated tumours but 
did not report frequency of SSI.3 
Antibiotic resistance is currently one of the most significant threats to patient safety.9 
Overuse of antibiotics and inappropriate prescribing are well recognized factors which 

 
 
 
 
 
 
 
Page 13 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
13 
contribute to antibiotic resistance. Furthermore, a survey of UK Dermatological surgeons, 
conducted in collaboration with the UK Dermatology Clinical Trials Network (UK DCTN), has 
shown that there is no agreed consensus on the timing of antibiotic prescribing, choice of 
antibiotic or length of antibiotic course.10 
To further inform the design of a pilot study, our extended UK DCTN surgical trainee 
research group has conducted a Critically Appraised Topic to assess the efficacy of 
perioperative antibiotics in reducing the risk of SSI following excision of ulcerated skin 
cancers, which confirmed the need for a well-designed RCT to answer this question.11 
5 
Study objectives/endpoints and outcome measures 
5.1 
Primary objectives 
• 
To determine the proportion of participants developing SSI following excision of 
ulcerated skin tumours in three Dermatology Departments: University Hospital of 
Wales, Cardiff; Churchill Hospital, Oxford and Queen Elizabeth Hospital, Birmingham 
5.2 
Secondary objectives 
• 
Feasibility work to inform the design of a future randomised controlled trial to 
investigate whether the use of peri-operative antibiotics in ulcerated skin tumours 
reduces the proportion of participants with SSI. 
5.3 
Primary outcomes measure  
The main objective is to determine the proportion of participants with SSI within four weeks of 
surgery. The research team will arrange to contact the participant four weeks after the 
procedure via a validated questionnaire (see details below) to determine whether they had 
any concerns about post-operative infection and what action was taken. SSI is broadly defined 
as the presence of one of the following criteria associated with the wound: abscess, cellulitis, 
discharge, delayed healing, discolouration, friable granulation tissue, unexpected pain/ 
tenderness, pocketing at base of wound, abnormal smell, wound breakdown.12 A systematic 
review has acknowledged the use of several different classifications for SSI and the lack of a 
standardised tool for diagnosing SSI.13 In response to this, Macefield et al. have developed a 
single patient and observer measure for post-discharge SSI assessment and have given us 
permission to use the tool in this study.14 

 
 
 
 
 
 
 
Page 14 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
14 
5.4 
Secondary outcomes measure(s)  
• 
The proportion of participants, over eight months from screened, eligible and willing to be 
randomised in a future trial to: 
a. no treatment 
b. topical treatment 
c. a few days of oral antibiotics 
d. a week of oral antibiotics  
• 
The proportion of participants recruited over eight months from eligible. 
• 
The proportion of participants completing the study (responding to the postal 
questionnaire) over eight months from eligible. 
• 
Assess feasibility of ‘wound selfies’ or wound photographs taken in the department as an 
objective outcome measure. 
• 
The proportion of participants with SSI who were prescribed oral antibiotics at the time of 
surgery. 
• 
Ulcerated tumour swab analysis results 
6 
Study design and setting 
Clinicians in the dermatology department will identify eligible participants at the time of initial 
consultation in outpatient clinic.  
Identification of potential participants will be by the clinical care team, or the clinical members 
of the research team involved in care of potential participants. Potential participants will be 
signposted to the research team by the clinical care team.  
Patients will be approached by a trained member of the clinical team or research nurse 
following clinical checks against the inclusion and exclusion criteria. They will be provided with 
an information leaflet and any other information about the study they request. The patient will 
be given sufficient information to ensure they fully understand the nature and risks of the study 
and are given as much time as they require to consider their participation. If they are willing to 
participate, they will be consented and admitted to the study at the time of surgery. Prior to 
the procedure relevant clinical information will be recorded in the Case Report Form (CRF) 
including demographic data, tumour site, tumour size, and size of tumoural ulceration. 
Participants will be asked whether they would prefer to be contacted via post or e-mail with 

 
 
 
 
 
 
 
Page 15 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
15 
the follow-up questionnaire. Histopathological data will be collected on tumour type when it is 
reported. Participants and clinicians will be asked whether they would agree for the patients 
to be randomised to no antibiotics, topical treatment eg. InadineTM dressings, a short course 
of antibiotics or a longer course of antibiotics in a future RCT. Following the procedure, 
information about whether oral antibiotics were prescribed will be recorded on a standardized 
CRF. All participants will be provided with the same information leaflet detailing standard post-
operative advice and further care will be as per each centre’s ‘standard clinical care’ which will 
also be recorded. Standard practice is usually for the patient to contact the local dermatology 
department where the procedure was carried out, or the patient’s local GP practice or for the 
patient to attend A&E.  
If participants are diagnosed with SSI they will be asked to take a photo of their wound on a 
camera phone and then to share the photo with the Cardiff University Centre for Trials 
Research (CTR) via email. Reeves et al. have described this practice as a ’wound selfie’ and 
report that the term is readily understood.15 If participants are not able to take of photo of their 
wound then they will be invited to attend the department to have a photograph taken by 
medical photography. Including both options will allow us to compare the feasibility of obtaining 
wound photos via each method. All participants will be sent a questionnaire by the research 
team four weeks following their procedure by post or by e-mail to enquire specifically whether 
the participant was diagnosed and treated for wound infection. These data will be collected by 
Cardiff University CTR who will co-ordinate the study. 
Additionally, all participants at University Hospital of Wales will have a surface swab taken 
from their ulcerated skin tumour and these will be analysed in the Public Health Wales 
laboratory at the University Hospital of Wales, Cardiff. The aim of this aspect of the study is to 
identify the most common organisms that colonise ulcerated tumours. Previous studies have 
commented on growth from ulcerated tumours, however it is not clear if this was conducted in 
a research laboratory setting.16 This will help to guide antibiotic choice in a future randomized 
controlled trial. 
6.1  
Risk assessment 
  
This study has been categorised as a Low Risk, where the level of risk is no higher than the 
risk of standard medical care.   

 
 
 
 
 
 
 
Page 16 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
16 
7 
Site and Investigator selection 
This study will be carried out at three centres: Cardiff and Vale University Health Board, 
Churchill Hospital, Oxford and Queen Elizabeth Hospital, Birmingham. 
8 
Participant selection  
Participants are eligible for the study if they meet all of the following inclusion criteria and none 
of the exclusion criteria apply.  
8.1 
Inclusion criteria 
• 
Dermatology Department patients > 18 years undergoing surgical excision of 
ulcerated skin cancer of any type affecting any body site 
8.2 
Exclusion criteria 
• 
Evidence of wound infection at the time of the procedure 
• 
Skin tumour removal undertaken using curettage or Mohs micrographic surgery  
• 
People without the capacity to consent for the study 
• 
People who are on systemic immunosuppressive treatment 
• 
People who are already taking oral antibiotics for any other reason 
9 
Recruitment, Screening and registration  
9.1 
Participant identification 
Clinicians in the dermatology department will identify eligible participants at the time of initial 
consultation.  
 
9.2 
Screening logs 
A screening log of all ineligible and eligible but not consented/not approached will be kept to 
inform any obstacles to enrolment in a future trial. 
9.3 
Recruitment rates 
A total of 311 participants will be recruited at an expected rate of 39 per month. This is based 
on a previous audit in this centre which demonstrated that 55 people would have been eligible 

 
 
 
 
 
 
 
Page 17 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
17 
for the study over a 3-week period. Assuming that just under half would agree to participate in 
the study, we anticipate recruiting 9 participants per week. 
9.4 
Informed consent 
Where eligibility is indicated, patients will be provided with a brief explanation of the study by 
the clinical team. Assenting patients will be provided with a full verbal explanation of the study 
and Participant Information Leaflet (PIL) to consider by the clinical team. This will include 
detailed information about the rationale, design, and personal implications of the study. 
Following information provision, patients will be able to consider participation until the planned 
time of surgery and will be given the opportunity to discuss the study with their family and other 
healthcare professionals before they are asked whether they would be willing to take part in 
the study. Assenting patients will then be invited to provide informed, written consent. 
Assessment of eligibility and the informed consent process will be undertaken by a member 
of the clinical team, who are qualified by training and/or experience in taking informed consent 
to GCP standards or by a research support office/ nurse. The right of the patient to refuse 
consent without giving reasons will be respected. Further, the patient will remain free to 
withdraw from the study at any time without giving reasons and without prejudicing any further 
treatment.  The participant’s written informed consent must be obtained using the Participant 
Consent Form, which follows the Participant Information Leaflet.  A record of the consent 
process detailing the date of consent and the version of the consent form used will be kept in 
the patient healthcare records. The original consent form will be retained in the Investigator 
Site File. 
Please note, only when written informed consent has been obtained from the participant and 
they have been enrolled into the study can they be considered a study participant. 
After the participant has entered the study, the investigator must remain free to give alternative 
treatment to that specified in the protocol, at any stage, if he/she feels it to be in the best 
interest of the participant. However, the reason for doing so should be recorded and the 
participant will remain within the study for the purpose of follow up and data analysis according 
to the treatment option to which he/she has been allocated. Similarly, the participant must 
remain free to withdraw at any time from the protocol treatment without giving reasons and 
without prejudicing his/her further treatment.  

 
 
 
 
 
 
 
Page 18 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
18 
9.5 
Registration  
9.5.1 Registration 
A record of the consent process detailing the date of consent will be kept in the patient 
healthcare records. To register a patient onto the OASIS study investigators or designee 
should complete the registration section of the Case Report Form (CRF). This will include: 
• 
Site code 
• 
Site name 
• 
Participant full name  
• 
Participant postal address or e-mail address 
• 
Participant phone number 
• 
Participant age  
• 
Participant gender 
• 
Date of consent of participant 
10 
Withdrawal & lost to follow-up 
10.1 
Withdrawal 
Participants have the right to withdraw consent for participation in any aspect of the study at 
any time. The participants care will not be affected at any time by declining to participate or 
withdrawing from the study.  
1. If a participant initially consents but subsequently withdraws from the study all their 
data will be removed. However participants cannot withdraw data after it has been 
anonymised for analysis. 
10.2 
Lost to follow up 
1. Participants will be identified as lost to follow up if we are unable to contact them four 
weeks after their procedure. 
2. Measures that we will take to try and get the missing information include three 
attempts to telephone or text the participants. If we are unable to contact the 
participant by telephone then and we will also send them a letter asking them to 
contact the study centre.’ 
11 
Study procedures 
The following are to be recorded before skin surgery on the CRF:  
 

 
 
 
 
 
 
 
Page 19 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
19 
 
  
o Whether the participant has been recruited to the study previously 
o Number of skin lesions being excised 
o Number of skin lesions being excised that are ulcerated  (if more than one 
ulcerated lesion, then the patient and researcher should agree on an index 
lesion for the OASIS study) 
o Suspected type of index skin cancer (clinical diagnosis) – to be confirmed on 
histology 
o Site of procedure(s) 
o Size of index skin cancer (mm) 
o Size of index tumoral ulceration 
 
Participants and the clinicians performing the procedure will be asked whether they would 
agree for the participant to be randomised to no antibiotics, topical treatment eg. InadineTM 
dressings, a short course of antibiotics or a longer course of antibiotics in a future RCT. 
 
The following will be recorded after skin surgery on the CRF: 
 
o Type of procedure 
o Whether InadineTM dressing applied to wound 
o Whether topical antibiotics applied to wound 
o Whether oral antibiotics prescribed 
 
 
A questionnaire [Appendix 1] will be sent to participants by post or email at four weeks. A 
stamped-addressed envelope will be sent with the questionnaire for the reply if required.  
11.1 
Assessments  
Assessment data required if participant develops suspected wound infection: 
 
o Photograph of wound (‘wound selfie’): the photos will be sent to the CTR to 
determine whether this is a feasible method of assessing wounds, however the 
photos will not be analysed. 
 
Figure 1.  Schedule of enrolment, interventions and assessments1  
Procedures 
Visits (insert visit numbers as appropriate) 
Screening 
Baseline 
(If concern 
about SSI) 
(Follow Up) 
Eligibility assessment 
X 
 
 
 
Informed consent 
 
X 
 
 
                                                          
1 Taken from the HRA CTIMP protocol template (2016). 

 
 
 
 
 
 
 
Page 20 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
20 
Demographics 
 
X 
 
 
Clinician / Participant 
agreement for future RCT 
 
X 
 
 
Procedure data 
 
X 
 
 
Skin swab  
(only CAVUHB 
participants ) 
 
X 
 
 
Wound photograph 
 
 
X 
 
Questionnaire 
 
 
 
X 
11.2 
Follow-up 
Final data will be collected by questionnaire four weeks after the procedure. Any further follow-
up appointments in the clinic will be based on clinical discretion and no further appointments 
will occur specifically for the study. 
11.3 Skin swabs (CAVUHB participants only) 
Participants enrolled to the study at the University Hospital of Wales, Cardiff will have swabs 
of ulcerated skin tumours taken and analysed in the Public Health Wales laboratory at the 
University Hospital of Wales, Cardiff.  
It is the responsibility of the study site to ensure that samples are appropriately labelled in 
accordance with the study procedures to comply with the current Data Protection legislation. 
Biological samples collected from participants as part of this study will be transported, stored, 
accessed and processed in accordance with national legislation relating to the use and storage 
of human tissue for research purposes and such activities shall at least meet the requirements 
as set out in the 2004 Human Tissue Act. 
Swabs of the ulcerated tumours will be taken with no prior cleaning prior to skin surgery. 
Completed swabs will be deposited in specimen collection baskets within the dermatology 
department and will be shipped to the laboratory via the standard portering system. 
Swabs will be cultured onto a range of non-selective and selective media. Bacterial pathogens 
will be semi-quantified and identified using MALDI-ToF and other tests where applicable. 
Microbiological infection will be determined according to local Standard Operating procedures, 

 
 
 
 
 
 
 
Page 21 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
21 
based upon UK national Standards in Microbiology Investigations (SMI) guidelines. After the 
skin swabs have been processed then they will be destroyed according to laboratory 
regulations. 
The aim of this is to identify the most common organisms that grow in ulcerated tumours which 
will help to guide antibiotic choice in a future randomised controlled trial.  
Currently, there is no consensus on which antibiotic would be most appropriate to reduce the 
risk of surgical site infection in ulcerated skin tumours. This may be partly explained by the 
paucity of data regarding pathogens of ulcerated skin tumours. One single-centre study in 
Australia isolated Staphylococcus aureus in 93 of 97 ulcerated lesions and gram-negative 
bacteria (including Klebsiella, Acinetobacter, Proteus, Serratia and Escherichia species) in 7 
of 97 ulcerated lesions.16 However, it is not clear whether this was conducted in a research 
laboratory setting or in a clinical setting where the laboratory would aim to identify the presence 
of known skin pathogens. 
12 Statistical considerations 
12.1 Sample size 
Given the wide range in reported SSI from published case series between 2-33%, we 
anticipate a SSI of approximately 10% in our participants with ulcerated skin tumours. Our aim 
is to recruit 311 participants with an intended sample size of 283 participants (allowing for a 
dropout rate of 10%). This will give a 95%CI of between 6.9% to 13.5%.  
12.2 Missing, unused & spurious data 
Any instances of unused or spurious data will be reported. If the quantity of missing data 
becomes an issue in this study, suitable analyses techniques will be used to impute data as 
required. 
12.3 Procedures for reporting deviation(s) from the original protocol 
Protocol deviations, non-compliances or breaches are departures from the approved 
protocol. Accidental protocol deviations can happen at any time. They must be adequately 
documented on the relevant forms and reported to the CTR. Deviations from the protocol 
which are found to frequently recur are not acceptable, will require immediate action and 
could potentially be classified as a serious breach. These will be reported by the PI to the 
CTR and will be followed up by the study manager. 

 
 
 
 
 
 
 
Page 22 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
22 
12.4 Inclusion in analysis 
All screened patients will be reported. For each analysis, only patients with relevant 
evaluable data will analysed. Where relevant, differences between those with and without 
the relevant evaluable data will be reported as a check for bias. 
13 Analysis 
13.1 Main analysis 
All analyses will report a proportion and 95% confidence interval. Where appropriate (i.e., if 
the proportion is <5%), the 95% confidence interval will be reported as per Wilson’s method. 
17 
14 Data Management 
14.1 Access to Data 
Direct access will be granted to authorised representatives from the sponsor and host 
institution for monitoring and/or audit of the study to ensure compliance with the relevant 
data protection legislation. 
14.2 Data Recording and Record Keeping 
The registration section of the Case Report Form (CRF) will include: 
• 
Site code 
• 
Participant full name  
• 
Participant address or email address  
 
Participant phone number 
• 
Participant age (at study enrolment) 
• 
Participant gender 
• 
Date of consent of participant 
The clinical part of the CRF will include:  
o Whether the participant has been recruited to the study previously 
o Number of skin lesions being excised 

 
 
 
 
 
 
 
Page 23 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
23 
o 
Number of skin lesions being excised that are ulcerated  (if more than one ulcerated 
lesion, then the patient and researcher should agree on an index lesion for the OASIS study) 
o 
Suspected type of index skin cancer (clinical diagnosis) – to be confirmed on histology 
o 
Site of procedure(s) 
o 
Size of index skin cancer (mm) 
o 
Size of index tumoral ulceration (mm) 
Participants and the clinicians performing the procedure will be asked whether they would 
agree for the participant to be randomised to no antibiotics, topical treatment eg. InadineTM 
dressings, a short course of antibiotics or a longer course of antibiotics in a future RCT. 
o 
Whether InadineTM dressing applied to wound 
o 
Whether topical antibiotics applied to wound 
o 
Whether oral antibiotics prescribed 
Type of procedure 
All data and personal information will be stored in locked filing cabinets in fireproof locations 
in restricted areas.  
Data processing and data sharing arrangements will be documented in the Statement of 
Activities between each participating site and the sponsor. Data from the clinical part of each 
CRF, together with the participant’s name, address and phone number should be returned to 
the CTR for data entry within four weeks of the visit via an encrypted secure file transfer service 
in accordance with the General Data Protection Regulation and Data Protection Act 2018. The 
CRF is to be retained at the local site.  In accordance with the principles of GCP, the PI is 
responsible for ensuring accuracy, completeness, legibility and timeliness of the data reported 
to the CTR. Data received by the CTR from participating study sites will be checked for 
missing, illegible or unusual values (range checks) and consistency over time. If missing or 
questionable data are identified, a data query will be raised on a data clarification form. The 
data clarification form will be sent to the relevant participating site. The site shall be requested 
to respond to the data query on the data clarification form. The case report form pages should 
not be altered. All answered data queries and corrections should be signed off and dated by 
a delegated member of staff at the relevant participating site. The completed data clarification 

 
 
 
 
 
 
 
Page 24 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
24 
form should be returned to the CTR and a copy retained at the site in a site file along with the 
participants’ CRFs. The CTR will send reminders for any overdue data. It is the site’s 
responsibility to submit complete and accurate data in timely manner. 
Each participant's name, address or e-mail address and phone number will be shared with the 
CTR so that the follow-up questionnaires can be sent from the CTR where the data will be 
collected. The participant’s phone number may be used to obtain missing information. All 
paper data and personal information will be stored in locked filing cabinets in fireproof locations 
in restricted areas. Electronic data will be stored on university servers, accessed via password 
protected, encrypted, firewall protected and backed up computers. All personal data will be 
confidentially destroyed at the end of the study. Once the participant's data has been collected 
they will be allocated a unique participant identification number (PID, assigned sequentially as 
each patient is registered). The PID will be used for the purpose of data analysis. The data 
generated by the study will be analysed by the CTR team led by Tim Pickles, Research 
Associate in Statistics and Dr Emma Thomas-Jones, Research Fellow/ Senior Trial Manager. 
14.3 Participant Confidentiality and Data Protection 
All investigators and study site staff must comply with the requirements of the General Data 
Protection Regulation and Data Protection Act 2018 with regards to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core principles. All 
research staff and delegated site staff will be trained in data protection and data management.  
14.4 Record Storage and Retention 
Essential documents pertaining to the trial shall not be destroyed without permission from the 
Sponsor. The TMF and ISF containing essential documents will be kept for a minimum of 5 
years after completion of study.  The CTR will send the Trial Master File to the sponsor at end 
of study for archiving. Documents (paper and electronic) will be retained in a secure location 
during and after the study has finished. Each PI at any participating site will archive the 
essential documents generated at the site for the agreed archiving period. 
 
 
 

 
 
 
 
 
 
 
Page 25 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
25 
 
Study data 
 
CRF 
Wound ‘selfies’ 
Questionnaire 
Demographic data 
X 
 
 
Procedure data 
X 
 
 
Follow up data 
 
 
X 
Skin swab result (UHW ppts only) 
X 
 
 
Photos of infected wounds 
 
X 
 
 
15 Protocol/GCP non-compliance 
The Principal Investigator will report any non-compliance to the study protocol or the 
conditions and principles of Good Clinical Practice to the CTR in writing as soon as they 
become aware of it.      
In the event that a serious breach of the protocol or GCP is suspected, this must be reported 
to the sponsor immediately. The sponsor will investigate the breach and any preventative and 
or corrective actions required will be undertaken by the research team. REC will be informed 
by the Chief Investigator if a serious breach is identified. 
16 End of Study definition 
The follow up period will continue for 4 weeks after the last participant’s last data item. 
The end of the study is defined as the date of final data capture to meet the study endpoints.  
In this case end of study is defined as the date on which the last participant is contacted by 
telephone four weeks after registration. 
CI or a delegate will notify the main REC of the end of a clinical study within 90 days of its 
completion or within 15 days if the study is terminated early.   

 
 
 
 
 
 
 
Page 26 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
26 
17 Regulatory Considerations 
17.1 Ethical and governance approval 
The study will be assessed for governance and legal compliance by HCRW. Once all checks 
are satisfied HCRW will issue HRA/HCRW approval. The study should not commence at any 
site until local confirmation of capacity and capability is also received via email by the CI/ PI.  
Before the start of the study, approval will be sought from HCRW and REC for the protocol, 
informed consent forms and other relevant documents Amendments that require review by 
HCRW and REC will not be implemented until approval is granted. The CI (or delegate) 
should submit any amendments to their National Coordinating Unit, HCRW. The HCRW 
Permissions Service will assess and approve the amendment. 
17.2 Data Protection 
The sponsor will act to preserve participant confidentiality and will not disclose or reproduce 
any information by which participants could be identified, except where specific consent is 
obtained.  Data will be stored in a secure manner and will be registered in accordance with 
the General Data Protection Regulations 2018.  
17.3 Indemnity 
This is an NHS-sponsored research study, and the NHS indemnity scheme therefore 
applies. If there is negligent harm during the study when the NHS body owes a duty of care 
to the person harmed, NHS indemnity covers NHS staff, medical academic staff with 
honorary contracts, and those conducting the trial. The NHS indemnity scheme does not 
cover non-negligent harm. 
17.4 Study sponsorship 
Cardiff and Vale University HB will act as Sponsor for the OASIS study. The HB shall be 
responsible for ensuring that the study is performed in accordance with the following: 
• 
Conditions and principles of Good Clinical Practice. 
• 
Declaration of Helsinki (1996).  
• 
UK Policy Framework for Health and Social Care Research (2017). 
• 
The Data Protection Act 1998. 
• 
Other regulatory requirements as appropriate. 

 
 
 
 
 
 
 
Page 27 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
27 
The Sponsor has/will be delegating certain responsibilities to Cardiff University (CTR), the CI, 
PIs, host sites and other stakeholder organisations as appropriate in accordance with the 
relevant agreement that is informed by regulation and study type. 
17.5 Funding 
The UK DCTN has awarded £10,000 for this study. Dermatology Forum for Wales has 
awarded £500 towards this study. The shortfall of £1,055.25 will be met by CAVUHB 
Dermatology Department Research Fund.  
18 
Quality Control and Assurance  
18.1 
Monitoring 
The clinical study risk assessment has been used to determine the intensity and focus of 
central and on-site monitoring activity in the OASIS study. Low monitoring levels will be 
employed. 
Investigators agree to allow study related monitoring, including audits and regulatory 
inspections, by providing direct access to source data/documents as required. Participant 
consent for this will be obtained. Findings generated from on-site and central monitoring will 
be shared with the Sponsor, CI, & PI. 
19 Publication policy 
In addition, the study has been developed with the help and funding support of the UK 
Dermatology Clinical Trials Network (UK DCTN) and full acknowledgement will be given in all 
publications. 
 
 

 
 
 
 
 
 
 
Page 28 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
28 
20 References 
1. Lomas A, Leornardi-Bee J, Bath-Hextall F. A systematic review of worldwide 
incidence of non-melanoma skin cancer. Br J Dermatol. 2012;166:1069-80. 
2. Weatherhead SC, Lawrence CM. Preoperative integrity of skin surface predicts 
infection risk. BMJ 2009;338:b516.  
3. Penington A. Ulceration and antihypertensive use are risk factors for infection after 
skin lesion excision. ANZ J Surge 2010;80:642-5. 
4. Wernham AGH, Fremlin GA, Verykiou S, Harper N, Chan S, Matin RN, Abbott RA. 
Feasibility analysis to evaluate the role of peri-operative antibiotics in reducing 
infection rates in ulcerated skin cancers. Br J Dermatol. 2016; 175 (suppl.S1) p107-
132.  
5. Dreher R et al. Antibiotic prophylaxis with cefazolin in reducing the infection rate of 
non-melanomcytic skin tumours: a randomized clinical trial. Eur J Plast Surg 
2017;40:133-136. 
6. Futoryan T, Grande D. Postoperative wound infection rates in dermatological surgery. 
Dermatol Surg 1995;21:509-14. 
7. Wrigh TI, Baddour L et al. Antibiotic prophylaxis in dermatologic surgery: Advisory 
statement2008. JAAD 2008;59:464-73. 
8. Heal C, Buettner P et al. Risk factors for wound infection after minor surgery in general 
practice. Med J Aust 2006;185:255-8. 
9.  Wernham AG1, Fremlin GA2, Verykiou S3, Harper N4, Chan SA5, Stembridge N6, 
Matin RN7, Abbott RA8. Survey of dermatologists demonstrates widely varying 
approach to perioperative antibiotic use - time for a randomized trial? Br J Dermatol. 
2016 Sep 2. doi: 10.1111/bjd.15025. [Epub ahead of print] 
10. The NHS antibiotic aware campaign, 
http://www.nhs.uk/NHSEngland/ARC/Pages/AboutARC.aspx 
11. Chan SA1, Wernham AGH et al.Do perioperative antibiotics reduce the risk of 
surgical site infection? A critically appraised topic. Br J Dermatol. In press. 
12. Cutting KF, Harding KG. Criteria for identifying wound infection. Journal of wound 
care 1994;3:198-201. 
13. Gibbons C, Bruce J et al. Identification of risk factors by systematic review and 
development of risk-adjusted models for surgical site infection. Health Technol 
Assess. 2011;15(30):1–156. iii-iv 

 
 
 
 
 
 
 
Page 29 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
29 
14. Macefield RC, Reeves BC, Milne TK, Nicholson A, Blencowe NS, Calvert M, Avery 
KNL, Messenger DE, Bamford R, Pinkney TD, Blazeby JM on behalf of the Bluebelle 
Study Group. Development of a single, practical measure of surgical site infection 
(SSI) for patient report or observer completion. J Inf Prev. 2017;18(4):170–79 
15. Reeves BC et al. A mixed-methods feasibility and external pilot study to inform a 
large pragmatic randomised controlled trial of the effects of surgical wound dressing 
strategies on surgical site infections (Bluebelle Phase B): study protocol for a 
randomised controlled trial. Trials 2017;18:401. 
16. Czarnecki D, Meehan C, Nash. Prevention of post excisional wound infections: a 
comparison of oral cephalexin with topical muprirocin and topical cetrimide-
chlorhexidene cream. International Journal of Dermatology 192:31;359-360. 
17. Wilson EB. Statistical Inference. Science 1926; 63(1629): 289-96. 
 
 

 
 
 
 
 
 
 
Page 30 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
30 
21 Appendices 
1. Questionnaire  
 
 
 

 
 
 
 
 
 
 
Page 31 of 32 
OASIS Study (IRAS number 243011) Protocol V1.3  04/12/19 
 
 
31 
Appendix 1: Questionnaire 
 
Since you left hospital after having surgery.... Response categories 
1 Was there redness spreading away from the wound? (erythema/cellulitis) Not at all / A little / Quite a bit / A lot 
2 Was the area around the wound warmer than the surrounding skin? 
 Not at all / A little / Quite a bit / A lot 
3 Was any part of the wound leaking fluid?  
 
 
 
Not at all / A little / Quite a bit / A lot 
a) Was it clear fluid? (serous exudate)  
 
 
 Not at all / A little / Quite a bit / A lot 
b) Was it blood-stained fluid? (haemoserous exudate)  
 
Not at all / A little / Quite a bit / A lot 
c) Was it thick and yellow/green fluid (pus/purulent exudate)  
 
Not at all / A little / Quite a bit / A lot 
d) I do not know 
4 Have the edges of any part of the wound separated/gaped open on their own 
accord? (spontaneous dehiscence)  
 
 
 
 
Not at all / A little / Quite a bit / A lot 
a) Did the skin separate?  
 
 
 
 
 
Not at all / A little / Quite a bit / A lot 
b) Did the deeper tissue separate?  
 
 
 
 
Not at all / A little / Quite a bit / A lot 
c) I do not know 
5 Has the area around the wound become swollen?  
 
 
Not at all / A little / Quite a bit / A lot 
6 Has the wound been smelly? 
 
 
 
 
 Not at all / A little / Quite a bit / A lot 
7 Has the wound been painful to touch?  
 
 
 
Not at all / A little / Quite a bit / A lot 
8 Have you had, or felt like you have had, a raised temperature or fever? Not at all / A little / Quite a bit / A lot 
(fever <38oC) 
9 Have you sought advice because of a problem with your wound, other than at a 
routine planned follow-up appointment?  
 
 
 
Yes / No 
If yes, please tell us who you sought advice from: 
a) A doctor or nurse at the GP surgery/medical centre/walk-in centre Yes / No 
b) A doctor or nurse at the hospital  
 
 
 
 
Yes / No 
c) A midwife or health visitor  
 
 
 
Yes / No 
d) Another health advisor  
 
 
 
 
 
Yes / No 
Please describe who the other health advisor was __________________ 
10 Has anything been put on the skin to cover the wound? (dressing)  
Yes / No 
If yes, 
a) Was this done by a doctor or nurse at the GP surgery/ medical centre/walkin 
centre?   
 
 
 
 
 
 
Yes / No 
 
b) Was this done by a nurse/midwife/health visitor at home? 
 
 Yes / No 
c) Was this done by you/your partner/friend/family member?  
 
Yes / No 
d) Was this done by a doctor/nurse/midwife at the hospital?  
 
Yes / No 
e) Please describe what was put on to cover the wound __________________ 
11 Have you been back into hospital for treatment with a problem with your 
wound?   
 
 
 
 
 
 
Yes / No 
 
12 Have you been given antibiotics for a problem with you wound?  Yes / No / Don’t know 
If yes, 
a) Were the antibiotics given as tablets/liquid?   
 
Yes / No / Don’t know 
b) Were the antibiotics given via drip?   
 
 
Yes / No / Don’t know 
If you know the name of the antibiotic(s) you have taken, please write it here 
__________________ 
13 Have the edges of your wound been deliberately separated by a doctor or 
nurse? 
 
 
 
 
 
 
 
 Yes / No / Don’t know 
 
14 Has your wound been scraped or cut to remove any unwanted tissue? 
(debridement of wound)  
 
 
 
 
 
Yes / No / Don’t know 
 
15 Has you wound been drained? (drainage of pus/abscess)  
 
Yes / No / Don’t know 
16 Have you had an operation under general anaesthetic for treatment of a 
problem with your wound?   
 
 
 
 
Yes / No / Don’t know